PSP Research LLC Takes Position in Palvella Therapeutics, Inc. $PVLA

PSP Research LLC acquired a new stake in Palvella Therapeutics, Inc. (NASDAQ:PVLA) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,084 shares of the company’s stock, valued at approximately $532,000.

Other institutional investors have also modified their holdings of the company. Archer Investment Corp acquired a new stake in shares of Palvella Therapeutics in the third quarter valued at $28,000. Russell Investments Group Ltd. acquired a new stake in shares of Palvella Therapeutics in the third quarter valued at $36,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Palvella Therapeutics in the fourth quarter valued at $167,000. Chung Wu Investment Group LLC lifted its holdings in shares of Palvella Therapeutics by 1,200.0% in the fourth quarter. Chung Wu Investment Group LLC now owns 2,600 shares of the company’s stock valued at $272,000 after buying an additional 2,400 shares during the period. Finally, AlphaQuest LLC acquired a new stake in shares of Palvella Therapeutics in the third quarter valued at $164,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Trading Up 4.0%

NASDAQ:PVLA opened at $109.20 on Wednesday. The firm has a market capitalization of $1.57 billion, a price-to-earnings ratio of -26.19 and a beta of -0.13. Palvella Therapeutics, Inc. has a 1-year low of $20.20 and a 1-year high of $151.18. The business’s fifty day moving average price is $123.39 and its 200 day moving average price is $104.88.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.30). Equities analysts forecast that Palvella Therapeutics, Inc. will post -5.43 earnings per share for the current year.

Insider Activity at Palvella Therapeutics

In related news, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total transaction of $507,592.98. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director George M. Jenkins purchased 4,000 shares of the company’s stock in a transaction that occurred on Friday, February 27th. The shares were acquired at an average cost of $125.00 per share, for a total transaction of $500,000.00. Following the completion of the transaction, the director directly owned 187,171 shares of the company’s stock, valued at $23,396,375. This trade represents a 2.18% increase in their position. The disclosure for this purchase is available in the SEC filing. 20.50% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. HC Wainwright upped their target price on Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Chardan Capital upped their target price on Palvella Therapeutics from $210.00 to $240.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. BTIG Research upped their target price on Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. TD Cowen reaffirmed a “buy” rating on shares of Palvella Therapeutics in a report on Monday, February 2nd. Finally, Stephens assumed coverage on Palvella Therapeutics in a report on Tuesday, May 12th. They set an “overweight” rating and a $220.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $199.53.

Palvella Therapeutics Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.